Vascular Endothelial Growth Factor Receptor-1 Expression in Breast Cancer and Its Correlation to Vascular Endothelial Growth Factor A
Authors:
Open Access
- 12 December 2013
- journal article
- research article
- Published by Wiley in International Journal of Breast Cancer
- Vol. 2013, 1-6
Abstract
VEGF-A is the most potent angiogenic factor in tumour angiogenesis. Its effects are mediated via two receptors VEGFR-1 and VEGFR-2. Primary aim of our study was to examine the expression of VEGFR-1 in breast cancer and its correlation to VEGF expression, lymph node status, tumour size, histological grade, and hormone receptor status. To examine the VEGFR-1 and VEGF expressions in tumour and surrounding tissue of 51 breast cancer patients, and in healthy breast tissue of 30 benign breast diseases patients, we used three-step immunohistochemical staining. VEGFR-1 and VEGF expressions were significantly increased in breast cancer tumour in relation to surrounding tissue (), and the VEGF expression was significantly increased in lymph node positive breast cancer patients (). VEGFR-1 and VEGF expressions were significantly higher in breast cancer tumour compared with healthy breast tissue (). Significant correlation between VEGF and VEGFR-1 expressions was found (). No significant correlations between VEGF and VEGFR-1 expressions and tumour size, histological grade, and hormone receptor status were found. Increased expression of VEGFR-1 and VEGF in breast cancer tumour and significant correlation between these proteins suggest the possible role of VEGF/VEGFR-1 signalization in breast cancer development, although VEGFR-1 potential prognostic value was not confirmed.
Keywords
Funding Information
- Ministry of Education, Culture and Science of Federation of Bosnia and Herzegovina
This publication has 29 references indexed in Scilit:
- Vascular endothelial growth factor receptor-1 mRNA overexpression in peripheral blood as a useful prognostic marker in breast cancerBreast Cancer Research, 2012
- Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacyProceedings of the National Academy of Sciences, 2011
- VEGF and Pleiotrophin Modulate the Immune Profile of Breast CancerCancers, 2010
- FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?Nature Reviews Cancer, 2008
- The vascular endothelial growth factor receptor (VEGFR‐1) supports growth and survival of human breast carcinomaInternational Journal of Cancer, 2006
- VEGF receptor signalling ? in control of vascular functionNature Reviews Molecular Cell Biology, 2006
- Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesisExperimental Cell Research, 2006
- Effect of Screening and Adjuvant Therapy on Mortality from Breast CancerNew England Journal of Medicine, 2005
- The biology of VEGF and its receptorsNature Medicine, 2003
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971